Author

A. Naranjo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Bahrami· 1 shared A. G. Henssen· 1 shared A. J. Salovin· 1 shared A. Kentsis· 1 shared A. Letai· 1 shared A. Pappo· 1 shared A. Peres· 1 shared A. Shelat· 1 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Bahrami

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma

M. I. Rosenberg, E. Greenstein, M. Buchkovich, M. Mikl, A. Peres, E. Santoni-Rugiu, D. Reshef, A. J. Salovin, D. L. Gibbs, M. S. Irwin, A. Naranjo, I. Ulitsky, P. A. de Alarcon, V. Weigman, G. Yaari, , J. M. Maris

The paper investigates OMAS in neuroblastoma, finding polyclonal B- and T-cell infiltration and TLS enrichment, linking them to autoimmune and anti-tumor responses.

bioRxiv · Dec 14, 2021Cancer Biology

Prohibitin is a prognostic marker of relapse and therapeutic target to block chemotherapy resistance in Wilms tumor

M. V. Ortiz, S. Ahmed, M. Burns, A. G. Henssen, T. Hollmann, I. MacArthur, S. Gunasekerea, L. Gaewsky, G. Bradwin, J. Ryan, A. Letai, Y. He, A. Naranjo, Y.-Y. Chi, M. LaQuaglia, , A. Kentsis

This study identifies prohibitin as a urine biomarker for Wilms tumor relapse and shows it promotes chemotherapy resistance by disrupting mitochondrial apoptosis.

bioRxiv · Dec 30, 2018Cancer Biology

MYCN Amplification and ATRX Mutations are Incompatible in Neuroblastoma

M. Zeineldin, S. Federico, X. Chen, Y. Fan, B. Xu, E. Stewart, X. Zhou, J. Jeon, L. Griffiths, J. Easton, H. Mulder, D. Yergeau, Y. Liu, J. Wu, C. Van Ryn, , M. Dyer

The paper shows that ATRX mutations and MYCN amplification are mutually exclusive in neuroblastoma and lead to synthetic lethality.

bioRxiv · Jul 29, 2018Cancer Biology